Delcath reports Q2 results; PDUFA for HEPZATO KIT on Aug 14

DELCATH SYSTEMS, INC.

PDUFA date August 14, 2023 for HEPZATO KIT NDA resubmission; FDA review ongoing.
Financing: $25M closed; up to $35M additional upon NDA approval; up to $25M on $10M quarterly revenue.
Q2 revenue $0.5M (down from $0.8M); R&D $3.6M (down from $5.6M); SG&A $4.8M (up from $4.5M).
Hired new CMO, SVP Finance, Director of Sales; treating patients at 3 Expanded Access sites.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

DELCATH SYSTEMS, INC. reported the second quarter ended June 30, 2023 results: revenue approximately $0.5 million.

Period: the second quarter ended June 30, 2023
Revenue: approximately $0.5 million
Result: reported results

Exact text from the filing

Total revenue for the three months ended June 30, 2023, was approximately $0.5 million, compared to $0.8 million for the prior year period, from our sales of CHEMOSAT in Europe.

View on SEC.gov

Browse all earnings releases →

DELCATH SYSTEMS, INC. filing history →

Source: SEC EDGAR

accession 0001628280-23-028674

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.